Ascendiant Capital Downgrades Cytori Therapeutics To Hold

Analysts at Ascendiant Capital downgraded Cytori Therapeutics CYTX from Buy to Hold and removed the price target of $4.00. Cytori Therapeutics shares have dropped 21.93% over the past 52 weeks, while the S&P 500 index has gained 13.56% in the same period. Cytori Therapeutics' shares dropped 30.95% to $1.45 in pre-market trading.